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Tumour angiogenesis is required for the growth of solid tumours
and metastasis. The significance of solid tumour angiogenesis as a
prognostic factor has been investigated in many human tumours
including gastric carcinoma (Maeda et al, 1995; Araya et al, 1997).
Among the various angiogenic factors, vascular endothelial
growth factor (VEGF) has been regarded as the most likely
candidate for the induction of angiogenesis in tumour growth
(Senger et al, 1993).
Nitric oxide (NO) is a biologically active mediator derived from
L-arginine, which is catalysed by NO synthase (NOS) (Moncada
et al, 1991). NO produces multiple effects that can influence the
outcome of metastasis and regulates vasodilatation which affect
tumour cell arrest in capillaries (Dong et al, 1994). In recent years,
some studies have shown that NOS is present in human tumour
tissues, including gynaecological cancer (Thomsen et al, 1994),
breast cancer (Thomsen et al, 1995), brain tumour (Cobbs et al,
1995), gastric cancer (Miles et al, 1996) and head and neck cancer
(Gallo et al, 1998).
Although many studies have shown that VEGF was over-
expressed by a variety of human cancer tissue, relatively little is
known about the behaviour of VEGF in the circulating level in
patients with gastric cancer. Moreover, previous investigations
have reported that several murine and human tumour cell lines
produce NO. However, still little is about the correlation between
the NO and VEGF in the circulating levels.
The aim of the present study was to investigate serum concen-
trations of VEGF and nitrite as an estimate of in vivo NO in
patients with gastric cancer as well as healthy individuals and
to examine the influence of tumour stage and tumour grade on
circulating levels of NO and VEGF.
MATERIALS AND METHODS
Study populations
The study consisted of 11 healthy individuals without any
evidence of disease (e.g. liver dysfunction, diabetes etc.) and 37
patients with primary gastric carcinoma who were treated at our
department. No patient had received chemotherapy or radiation
therapy before surgery. None of the subjects had renal dysfunction,
infection, or gastrointestinal bleeding. In addition, none of them
received any antibiotics or vasoactive drugs before the sera were
obtained.
The patients ranged in age from 32 to 81 years (mean age 61
years). There were 21 men and 16 women. To investigate whether
NO and VEGF concentrations in serum could reflect the tumour
stage, we classified the patients according to 1997 TNM classifica-
tion (Sobin and Wittekind, 1997), and measured the VEGF and
estimated NO concentrations in their serum. In addition, patients
were categorized into three groups according to tumour grade.
Patients’ characteristics are summarized in Table 1.
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Laboratory assay
Sera were obtained from patients who had not undergone surgery.
All patients and control subjects fasted for at least 12 h. Venous
blood samples were drawn into a tube and allowed to clot for
20 min before centrifugation at 3000 rpm for 10 min. The serum
samples were stored at –80°C until analysis. The VEGF levels in
preoperative sera of patients and healthy donors were measured
by using the quantitative sandwich immunoassay technique
(Quantikine, R&D Systems, UK).
Griess reaction was the method of choice to evaluate serum
nitrite/nitrate levels with the following modifications. In vivo NO
concentration* estimation was done via analysis of nitrites (NO–2)
in serum without reduction of nitrates (NO–3) step, as it has
recently been suggested that inclusion of nitrates in the determina-
tion of in vivo NO* causes an overestimation of approximately
500% than when NO was measured by the haemoglobin reaction
(Privat et al, 1997). Briefly, serum samples were deproteinized
with 0.6 N perchloric acid and the supernatants were assayed for
nitrite concentration through recording the absorbance at 540 nm.
NOin vivo = (ODserum – ODserum blank w / H20) ´ F mM
F = 100 (conversion factor from A540 to mM nitrite from standard
curve) due to the equations valid for oxygenated solutions (1)–(3)
(Hevel and Marletta, 1994).
Table 1 Characteristics of 37 patients with gastric cancer
Characteristics No. of patients
Mean age (range) 61 years (32–81)
Sex
Male 21
Female 16
Tumour stage
14
28
31 5
41 0
Tumour grade (G)
G1 6
G2 12
G3 19
Tumour location
Upper-third stomach 6
Middle-third stomach 9
Lower-third stomach 22
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Figure 1 Serum VEGF-165 levels (pg ml-1) in control subjects and gastric
cancer patients
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Figure 2 Serum NO levels in control group and gastric cancer patients1632 A Erog ˘lu et al
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2NO* + O2 ® 2NO2* (1)
NO* + NO2* ® N2 O3 ® 2 NO2
– (2)
+2NO2* ® N2 O4 + H2 O ® NO2
– + NO3
– (3)
3NO* ® 3 NO2
–
The NO and VEGF values for each serum sample were obtained
from duplicate assays.
Statistical analysis
Results were expressed as the mean ± standard deviation (s.d.).
Comparison of VEGF and NO levels between the groups was eval-
uated by analysis of variance (ANOVA) test. The relationships
between the NO and VEGF levels were reported as Spearman
product-moment correlation coefficient (rs). Cut-off value for
VEGF and NO was calculated by using receiver operating charac-
teristic (ROC) analysis. Areas under the ROC curves of VEGF and
NO were also compared. For all tests, a P-value less than 0.05 was
accepted as significant.
The statistical analysis was performed by Statistical Package
for Social Sciences (SPSS for MS Windows Release 5.0, Chicago,
IL, USA).
RESULTS
Two major histological types considered in this study were adeno-
carcinoma, diagnosed in 28 patients, and mucinous carcinoma,
defined as when a mucinous component was evident in more than
50% of the tumour section in nine patients.
Tumours were staged by TNM classification. Accordingly, there
were four patients in stage 1 (T1 N0 M0 in one, T1 N1 M0 in two,
T2 N0 M0 in one), eight in stage 2 (T2 N1 M0 in four, T3 N0 M0
in four), 15 in stage 3 (T3 N1 M0 in six, T3 N2 M0 in eight,
T4 N0 M0 in one) and ten in stage 4 (T3 N3 M0 in four, T4 N2 M0
in two, T4 N2 M1 in two, T4 N3 M1 in two). The distribution of
patients according to the degree of histological differentiation of
the tumour was as follows: well-differentiated tumours (G1) in six
patients, moderately differentiated (G2) in 12, poorly differen-
tiated tumours (G3) in 19 patients.
No significant correlation was seen between histological type of
the tumour and serum VEGF concentrations. Moderately differen-
tiated and poorly differentiated tumours were related to an
increased mean level of VEGF, 695.2 ± 311.4 pg ml–1 and 759.3 ±
400.5 pg ml–1 respectively, compared with well-differentiated
tumours (349.1 ± 247.3 pg ml–1), but these differences were not
found as statistically significant (P > 0.05). Also, there was no
significant difference between men and women and between
tumour locations (P > 0.05).
The distribution of the mean level of VEGF on the basis tumour
stage was as follows: 166 ± 52.4 pg ml–1 (range 122.6–242.3) in
stage 1; 248.1 ± 107.7 pg ml–1 (range 168.2–504) in stage 2; 658.6
± 324 pg ml–1 (range 209.6–1273) in stage 3; and 1233.6 ± 317.3
pg ml–1 (range 798.7–1777) in stage 4. It was seen that large
tumour burden was associated with increased level of VEGF.
The mean level of VEGF in sera from healthy individuals was
94.5 ± 55.7 pg ml–1 (range 36.1–218). A statistically significant
difference in serum VEGF concentrations was found between the
groups (P < 0.001) (Figure 1).
As shown in Figure 2, serum NO levels in patients with stage 1
gastric carcinoma (mean 11 ± 2.9 mM, range 8–14) were signifi-
cantly higher than those in healthy individuals (mean 8.5 ± 4.3 mM,
range 2–11).
The ANOVA test also showed a significant difference in serum
NO concentrations among stage 1, stage 2 (mean 20.4 ± 4.5 mM,
range 13–27), stage 3 (mean 36.8 ± 7.4 mM, range 26–53) and
stage 4 disease (mean 55.6 ± 17.5 mM, range 38–95) (P < 0.001).
On the other hand, the serum nitrite level was higher in grade 3
tumour patients (mean 40 ± 14.8 mM) compared with grade 1
(mean 26.6 ± 10.8 mM) or grade 2 tumour patients (mean 32 ± 24.3
mM). But, these differences were not statistically significant
(P > 0.05). Moreover, there was no significant difference with
respect to patient gender and tumour location. In addition, when
we correlated serum VEGF level with serum NO concentration,
we found that the increased VEGF level was statistically associ-
ated with an elevated nitrite level (rs = 0.8 and P < 0.0001).
By ROC analysis, the sensitivity and the specificity for VEGF
and NO were computed as 91.9% and 81.8%; and 89.2% and
90.9% respectively. The cut-off levels of serum VEGF and NO
concentrations were found to be 149.9 pg ml–1 and 13 mM respec-
tively. Area under the curves of VEGF and NO was computed
as 0.9619 ± 0.026 and 0.9582 ± 0.0257 respectively. There was
no statistical differences between the area under two curves
(Figure 3).
DISCUSSION
The importance of tumour angiogenesis in the process of tumour
growth and progression in solid tumour has been widely accepted
(Fidler and Ellis, 1994). VEGF, also known as vascular perme-
ability factor (VPF), is a 34–42 kDa multifunctional cytokine that
is an important regulator of angiogenesis. VEGF has been shown
to play an important role in the development and metastasis of the
solid tumours (Senger et al, 1993).
Previous studies have demonstrated that VEGF was over-
expressed by a variety of human cancer tissues. In recent years,
some authors have also reported on the relationship between
tumour angiogenesis and prognosis in patients with gastric carci-
noma, both disease-free and overall survival rates decrease with
increasing microvessel count (Maeda et al, 1995; Araya et al,
1997). Moreover, multivariate analysis indicated that the over-
expression of VEGF is an independent prognostic factor in gastric
cancer patients (Maeda et al, 1996). However, relatively little is
known about the circulating level of VEGF. A recent study has
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shown that serum VEGF level was significantly elevated in some
population of cancer patients including those of gastric cancer
compared with control subjects (Yamamoto et al, 1996).
In the present study, we determinated serum VEGF concentra-
tions in patients with gastric carcinoma as well as healthy indi-
viduals. Here we reported our findings from serum samples from
different tumour stages of human gastric cancer. Elevated serum
levels of VEGF were found in advanced disease patients when
compared to early-stage disease and healthy individuals. This
suggests that high VEGF level is related to advanced tumour stage.
Although the number of patients studied was small, we suggest
that VEGF assay may be useful in predicting the advanced gastric
carcinoma.
Important steps in angiogenesis include invasion of the vascular
wall of the parent vessel by activated endothelial cells which then
proliferate, migrate and form the lumen of the new vessel (Fidler
and Ellis, 1994). The role of NO in tumour angiogenesis is not
sufficiently understood. Although NO was first identified in
endothelial cells, it is well known to be generated by a variety of
solid human tumours.
Previous investigations have shown NO to cause increased
tumour blood flow, oedema and vascular permeability (Nathan and
Xie, 1994; Fukumura et al, 1997). NO production by tumour cells
may influence tumour growth and metastasis (Pipili-Synetos et al,
1993; Jenkins et al, 1995). The functions of NO in tumours poten-
tially facilitate tumour growth. Moreover, tumour blood flow and
vessel diameter of experimental tumours in mice decreased after
the treatment with NOS inhibitors (Andrade et al, 1992; Thomsen
et al, 1997).
NOS activity was observed in solid human tumour tissues,
including gynaecological cancer (Thomsen et al, 1994), breast
cancer (Thomsen et al, 1995), brain tumour (Cobbs et al, 1995),
gastric cancer (Miles et al, 1996) and head and neck cancer (Gallo
et al, 1998). Furthermore, this enzyme activity in the tumour
tissues correlated with grade.
In a recent study, it was suggested that the increased plasma
nitrite/nitrate levels were correlated to tumour volume in patients
with hepatocellular carcinoma (Moriyama et al, 1997). In the
present study, we have estimated serum NO as nitrite in gastric
cancer patients and control subjects. We have investigated the
effect of tumour stage on the production of NO in sera of gastric
cancer patients. A striking relationship was found between serum
NO levels and tumour stage (P < 0.001). Although the serum NO
level was elevated in high-grade tumour compared with low-grade
tumour, this difference was found to be statistically insignificant.
The slightly lower serum NO concentrations were observed in
stage I disease; however, the highest serum level of NO was found
in stage 4 tumour. Serum NO levels were higher in patients with
advanced gastric cancer and were also positively correlated with
increased VEGF levels.
Recently, Gallo et al (1998) reported an interesting analysis of
NO production and angiogenesis in 27 patients with head and neck
cancer. Their results revealed a strong positive correlation between
the expression of NOS and tumour angiogenesis and tumour
progression. To our knowledge, there has been no report about the
relationship between NO and VEGF concentration in sera in
gastric cancer patients. We therefore examined whether serum NO
levels correlate with serum VEGF levels.
In this study, we show that an increase in NO levels is found in
gastric cancer, is associated with elevated VEGF levels and corre-
lates with tumour stage. This positive correlation between tumour
stage and serum NO and VEGF levels in patients with gastric
cancer suggests that NO might play a role in the biology of the
gastric cancer. The relationship observed between tumour stage,
VEGF and NO may be due to ongoing neovascularization associ-
ated with increasing tumour burden. It needs further studies to
elucidate a precise role for the NO pathway in tumour angiogen-
esis. In addition, antiangiogenetic therapy has been investigated
and may be a new treatment for metastatic disease in the future
(Folkman, 1997). Accordingly, it is also recommended that the
monitoring of VEGF and NO levels in the circulation may be
useful to assess the anti-angiogenetic therapy.
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